Literature DB >> 10677236

Alpha-ketoacids are potent slow binding inhibitors of the hepatitis C virus NS3 protease.

F Narjes1, M Brunetti, S Colarusso, B Gerlach, U Koch, G Biasiol, D Fattori, R De Francesco, V G Matassa, C Steinkühler.   

Abstract

The replication of the hepatitis C virus (HCV), an important human pathogen, crucially depends on the proteolytic maturation of a large viral polyprotein precursor. The viral nonstructural protein 3 (NS3) harbors a serine protease domain that plays a pivotal role in this process, being responsible for four out of the five cleavage events that occur in the nonstructural region of the HCV polyprotein. We here show that hexapeptide, tetrapeptide, and tripeptide alpha-ketoacids are potent, slow binding inhibitors of this enzyme. Their mechanism of inhibition involves the rapid formation of a noncovalent collision complex in a diffusion-limited, electrostatically driven association reaction followed by a slow isomerization step resulting in a very tight complex. pH dependence experiments point to the protonated catalytic His 57 as an important determinant for formation of the collision complex. K(i) values of the collision complexes vary between 3 nM and 18.5 microM and largely depend on contacts made by the peptide moiety of the inhibitors. Site-directed mutagenesis indicates that Lys 136 selectively participates in stabilization of the tight complex but not of the collision complex. A significant solvent isotope effect on the isomerization rate constant is suggestive of a chemical step being rate limiting for tight complex formation. The potency of these compounds is dominated by their slow dissociation rate constants, leading to complex half-lives of 11-48 h and overall K(i) values between 10 pM and 67 nM. The rate constants describing the formation and the dissociation of the tight complex are relatively independent of the peptide moiety and appear to predominantly reflect the intrinsic chemical reactivity of the ketoacid function.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10677236     DOI: 10.1021/bi9924260

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  8 in total

1.  Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain.

Authors:  G Barbato; D O Cicero; F Cordier; F Narjes; B Gerlach; S Sambucini; S Grzesiek; V G Matassa; R De Francesco; R Bazzo
Journal:  EMBO J       Date:  2000-03-15       Impact factor: 11.598

2.  Ribonucleoside analogue that blocks replication of bovine viral diarrhea and hepatitis C viruses in culture.

Authors:  Lieven J Stuyver; Tony Whitaker; Tamara R McBrayer; Brenda I Hernandez-Santiago; Stefania Lostia; Phillip M Tharnish; Mangala Ramesh; Chung K Chu; Robert Jordan; Junxing Shi; Suguna Rachakonda; Kyoichi A Watanabe; Michael J Otto; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2003-01       Impact factor: 5.191

3.  Can Relative Binding Free Energy Predict Selectivity of Reversible Covalent Inhibitors?

Authors:  Payal Chatterjee; Wesley M Botello-Smith; Han Zhang; Li Qian; Abdelaziz Alsamarah; David Kent; Jerome J Lacroix; Michel Baudry; Yun Luo
Journal:  J Am Chem Soc       Date:  2017-11-29       Impact factor: 15.419

4.  Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein.

Authors:  M Pallaoro; A Lahm; G Biasiol; M Brunetti; C Nardella; L Orsatti; F Bonelli; S Orrù; F Narjes; C Steinkühler
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

5.  In vitro selection and characterization of hepatitis C virus serine protease variants resistant to an active-site peptide inhibitor.

Authors:  Caterina Trozzi; Linda Bartholomew; Alessandra Ceccacci; Gabriella Biasiol; Laura Pacini; Sergio Altamura; Frank Narjes; Ester Muraglia; Giacomo Paonessa; Uwe Koch; Raffaele De Francesco; Christian Steinkuhler; Giovanni Migliaccio
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

6.  Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease.

Authors:  Robert B Perni; Susan J Almquist; Randal A Byrn; Gurudatt Chandorkar; Pravin R Chaturvedi; Lawrence F Courtney; Caroline J Decker; Kirk Dinehart; Cynthia A Gates; Scott L Harbeson; Angela Heiser; Gururaj Kalkeri; Elaine Kolaczkowski; Kai Lin; Yu-Ping Luong; B Govinda Rao; William P Taylor; John A Thomson; Roger D Tung; Yunyi Wei; Ann D Kwong; Chao Lin
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

7.  Potent Inhibitors of Hepatitis C Virus NS3 Protease: Employment of a Difluoromethyl Group as a Hydrogen-Bond Donor.

Authors:  Barbara Zheng; Stanley V D'Andrea; Li-Qiang Sun; Alan Xiangdong Wang; Yan Chen; Peter Hrnciar; Jacques Friborg; Paul Falk; Dennis Hernandez; Fei Yu; Amy K Sheaffer; Jay O Knipe; Kathy Mosure; Ramkumar Rajamani; Andrew C Good; Kevin Kish; Jeffrey Tredup; Herbert E Klei; Manjula Paruchuri; Alicia Ng; Qi Gao; Richard A Rampulla; Arvind Mathur; Nicholas A Meanwell; Fiona McPhee; Paul M Scola
Journal:  ACS Med Chem Lett       Date:  2018-01-19       Impact factor: 4.345

8.  Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers.

Authors:  Valerie A Braz; Leslie A Holladay; Mary D Barkley
Journal:  Biochemistry       Date:  2010-01-26       Impact factor: 3.162

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.